MannKind wins FDA approval for Furoscix ReadyFlow autoinjector to treat edema in adults with heart failure or CKD

MNKD•2026-07-24

FDA approval for Furoscix ReadyFlow

MannKind won FDA clearance for Furoscix ReadyFlow, an at-home autoinjector of subcutaneous furosemide for edema in adults with heart failure or CKD.

Product launch is targeted by the end of August 2026, and the company said the device cuts administration time to under 10 seconds from about five hours for the on-body infusor.

Sources

MannKind wins FDA approval for Furoscix ReadyFlow autoinjector to treat edema in adults with heart failure or CKD

Publicnow

MannKind wins FDA approval for Furoscix ReadyFlow autoinjector to treat edema in adults with heart failure or CKD

FDA approval for Furoscix ReadyFlow

Related News

Nasdaq Trade Halt <BIOT.O> Volatility Trading Pause at 01:50 PM

Laser Photonics appoints Rosenfield as new independent auditor, replacing Weinberg & Co

W.Africa Crude - Nigerian September loadings to jump

Sources

MannKind wins FDA approval for Furoscix ReadyFlow autoinjector to treat edema in adults with heart failure or CKD

Nasdaq trade halt continues <PLTS.O> reason not available at 03:01 PM

Nasdaq trade halt continues <PC.O> reason not available at 02:28 PM